News

Clinical Trial News Press Release

4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis

4Moving Biotech’s Participation at ACR Conference 2024

November 7, 2024

4Moving Biotech upcoming conferences until the end of the year 2024

October 8, 2024

The final meeting of the OA-BIO consortium

September 18, 2024

The launch of the official LinkedIn page for the OA-BIO European Biomarker Consortium

September 10, 2024

Gouvernance News

Luc Boblet joins 4Moving Biotech as its Chief Executive Officer

End of content

Get In Touch ×